Monitor upcoming ERAS-4001 Phase 1 data expected in H2 2026 and ERAS-0015 data in H1 2027 for signs of efficacy; the cash runway supports multiple registration-enabling trials through 2028, reducing near-term dilution risk.
Drugs in focus
ERAS drug pipeline →ERAS-0015
◆ Mixed Named in this press release- Impact
- Phase
- Phase 1
- Time to market
- ~3-5 years, assuming registration-enabling trials initiate in 2027 and a potential approval by ~2029-2030
- Next catalyst
- None dated
What to watchERAS-0015 Phase 1 data is genuinely strong (57-62% response rates in difficult-to-treat tumors) but the stock carries heavy legal baggage, a securities class action and patent-infringement allegations from Revolution Medicines. The stock recovered from its April 48% crash to ~$18; watch for the August 10, 2026 lead-plaintiff deadline and any developments in the Revolution Medicines patent dispute, which could swing shares sharply. The registration-enabling trial initiations in H1 2027 are the next major de-risking catalyst.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $15.66entry
- T+1 · 17h ago −3.51%α −1.60% · $15.11
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Erasca reported a Q3 2026 net loss of $51.3M ($0.15/share), wider than the $30.6M loss a year ago, driven by increased R&D spending. The company highlighted FDA Fast Track Designation for ERAS-0015 in pancreatic cancer and a strong cash position of $948M following a $632.5M public offering, funding key milestones through 2027-2028.
Key Financial Metrics
Key Facts
- Net loss of $51.3M ($0.15/share) for Q3 2026 vs $30.6M ($0.11/share) in Q3 2025
- Cash, cash equivalents, and marketable securities of $947.8M as of Sep 30, 2026, up from $341.8M at Dec 31, 2025
- Completed upsized public offering in July 2026 raising ~$632.5M in gross proceeds
- FDA Fast Track Designation granted to ERAS-0015 for metastatic pancreatic adenocarcinoma in August 2026
- R&D expenses rose to $47.2M from $22.5M YoY, driven by clinical trial and preclinical costs
- Key upcoming milestones: Phase 1 ERAS-0015 data H1 2027, Phase 3 pancreatic trial initiation 2027, Phase 1 ERAS-4001 data H2 2026
Financial Impact
Net loss increased by $20.7M YoY; cash position strengthened by $606M from year-end 2025 due to $632.5M offering
Risk Factors
- Clinical-stage company with no approved products; net losses expected to continue
- R&D expenses are rising sharply as trials advance, potentially accelerating cash burn
- Forward-looking statements subject to clinical trial risks and regulatory uncertainties
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3402156 |
Track record
26 reports on ERAS
4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +95.35% at T+60 after the Apr 27, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $15.21 Now $15.11 −0.66% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.31 Now $15.11 −1.31% settles Feb 12
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.35 Now $15.11 −1.56% settles Feb 12
- Nov 12, 20264d ago Press Release Neutral 4/10 Viewing Entry $15.66 Now $15.11 −3.51% settles Feb 11
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $14.64 Now $15.11 +3.21% settles Feb 1
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $13.39 Now $15.11 +12.85% settles Jan 13
- Aug 24, 202612w ago 8-K Bullish 5/10 Entry $17.60 Now $15.11 −14.15% settles Nov 17
- Aug 17, 202613w ago 144 Neutral 3/10 Entry $18.28 to $15.61 Now $15.11 −17.34% ▼ −14.61% −11.84% vs SPY
- Aug 13, 202613w ago Institutional Cluster Bullish 6/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
- Aug 12, 202613w ago 3 Neutral 2/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers